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IMPORTANCE Healthcare overuse, the delivery of low-value services, is increasingly
recognized as a critical problem. However, little is known about the comparative
effectiveness of alternate formats for presenting benefits and harms information to patients
as a strategy to reduce overuse.
OBJECTIVE To examine the effect of different benefits and harms presentations on patients’
intentions to accept low-value or potentially low-value screening services (prostate cancer
screening in men ages 50-69 years; osteoporosis screening in low-risk women ages 50-64
years; or colorectal cancer screening in men and women ages 76-85 years).
DESIGN, SETTING, AND PARTICIPANTS Randomized clinical trial of 775 individuals eligible to
receive information about any 1 of the 3 screening services and scheduled for a visit with their
clinician. Participants were randomized to 1 of 4 intervention arms that differed in terms of
presentation format: words, numbers, numbers plus narrative, and numbers plus framed
presentation. The trial was conducted from September 2012 to June 2014 at 2 family
medicine and 2 internal medicine practices affiliated with the Duke Primary Care Research
Consortium. The data were analyzed betweenMay and September of 2015.
INTERVENTIONS One-page evidence-based decision support sheets on each of the 3
screening services, with benefits and harms information presented in 1 of 4 formats: words,
numbers, numbers plus narratives, or numbers plus a framed presentation.
MAIN OUTCOMES ANDMEASURES The primary outcomewas change in intention to accept
screening (on a response scale from 1 to 5). Our secondary outcomes included general and
disease-specific knowledge, perceived risk and consequences of disease, screening attitudes,
perceived net benefit of screening, values clarity, and self-efficacy for screening.
RESULTS We enrolled and randomly allocated 775 individuals, aged 50 to 85 years, to 1 of 4
intervention arms: 195 to words, 192 to numbers, 196 to narrative, and 192 to framed
formats. Intentions to accept screening were high before the intervention and change in
intentions did not differ across intervention arms (words, −0.07; numbers, −0.05; numbers
plus narrative, −0.12; numbers plus framed presentation, −0.02; P = .57 for all comparisons).
Change in other outcomes also showed no difference across intervention arms. Results were
similar when stratified by screening service.
CONCLUSIONS AND RELEVANCE Single, brief, written decision support interventions, such as
the ones in this study, are unlikely to be sufficient to change intentions for screening.
Alternate and additional interventions are needed to reduce overused screening services.
TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT01694784
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D eliveryof low-valueservices, alsoknownashealthcareoveruse, is a critical problem for US health care. Low-value services are those in which the degree of ben-
efit does not justify the harms and costs.1 The United States
spends an estimated $192 billion annually ondelivery of such
services.2 This results in physical, psychological, and finan-
cial harms; hassle; and opportunity costs without potential
benefit for patients.3
However, thebestways to addresshealth care overuse are
unknown. It isunclearwhetherthesamestrategies that increase
useofeffectivehealthcareservicesworkequallywell to reduce
overuseof health care services.4 Furthermore, little compara-
tiveeffectiveness research is available toguidepreventionand
deimplementation of strategies targeted at overuse.5,6
Any comprehensive strategy to address health care over-
use must include messages for patients.6 While the message
mightvarybasedonseveral factors,expertsagree thatkeycom-
ponents to inform patients about health care services include
the likelihood of acquiring and dying from the targeted dis-
ease; thebenefits andharmsof thehealth care service; anden-
couragement tomakeadecisionaboutwhether tohave theser-
vice basedon thepatient’s individual preferences andvalues.7
The effectiveness of such messages is likely to be influ-
enced by many factors, including their presentation format.
Convincing literature8 suggests that words describing prob-
abilitydonothavesharedmeaningandthat the formatofnum-
bers has substantial impact on understanding and behavioral
intention.9,10 Furthermore, different narratives and framed
presentation formats differentially affect these same
outcomes.11-13 However, to our knowledge, no studies have
compared the effectiveness of these presentation formats in
reducing intentions or behavior for low-value or potentially
low-value screening services.
Therefore, our goal was to examine the comparative ef-
fectiveness of 4 alternate formats for presenting benefits and
harms information in reducing intentions for screening and
changing secondary behavioral and decision-making out-
comes for patients eligible for 1 of 3 low-value or potentially
low-value screening services.
Methods
Study Overview and Setting
We conducted a randomized clinical trial in a convenience
sample of four community-based practices (2 family medi-
cine, 2 internal medicine), with 26 810 patients and 32 clini-
cians, that were affiliated with the Duke Primary Care Re-
searchConsortium (PCRC). The institutional reviewboards at
the University of North Carolina and Duke University ap-
proved the study, and a data safety monitoring committee
monitored the study. The trial protocol is provided in
Supplement 1.
Participants and Their Recruitment
Fromweekly practice patient lists, study staff recruited a con-
secutive sample of individuals, ages 50 to 85 years, who re-
ceived continuing care for more than 1 year at any of the par-
ticipatingPCRCsites, hadanupcomingmedical visitwith their
clinician, and were eligible to receive information about any 1
of the3screeningservicesof interest.Theseserviceshadeither
net harm at the population level (ie, prostate cancer screening
inmen ages 50-69 years) or small net benefit (making it likely
that some individuals would benefit and some be harmed; ie,
osteoporosis screening in low-riskwomen ages 50-64 years or
colorectal cancer screening in men and women ages 76-85
years).We chose these services because they represent a spec-
trum of net benefit, encompass a variety of test types (a labo-
ratory test, aprocedural test, anda radiographic study), andare
applied toa spectrumofadultpatients.Becauseagegroupsdid
not overlap, each patient was eligible for only 1 service. Al-
though we initially planned to include cardiovascular screen-
ing in low-risk men and women as an additional service, we
dropped this service before recruitment given lownumbers of
eligible patients at study sites. Additional inclusion and exclu-
sion criteria are published elsewhere.14
We identified eligible patients for each service through
electronicclinical recordsandconsecutively sampled themun-
til we reached target enrollment (n = 775). Patients provided
written informed consent and were given $35 in compensa-
tion forparticipating.Westratified recruitmentby site andser-
vice and attempted to recruit at least 25% of the sample with
no prior screening for each service (although this was not al-
ways possible).Wemailed letters to all potentially eligible pa-
tientsandthenfollowedupwithupto3telephonecalls to reach
the patient and verify eligibility.
Procedures
Staff invited eligible participants to a study visit before or af-
ter a regularly scheduledphysician’s appointmentor at a sepa-
rate time if necessary. At the study visit, patients gave in-
formedconsent, completedapreinterventionsurvey, andwere
assigned using central computerized randomization to 1 of 4
intervention arms for a single screening service. Randomiza-
tionwas stratified by site, screening service, andprior screen-
ingwith allocation concealed fromstaff in a computerizedda-
tabase until after baseline survey completion. Patients were
told only that theywere participating in a study about how to
best communicatewithpatientsabout screening.Patients read
their 1 assigned evidence-based decision support sheet and
completed postintervention surveys but did not discuss the
materials with their clinicians.
Intervention
The intervention consisted of 1-page, written, evidence-based
decisionsupportsheets foreachof thescreeningservices.These
were based on US Preventive Services Task Force (USPSTF)
recommendations,15-18weredeveloped throughanexpert con-
sensus process (that included 1 former USPSTFmember), and
were written at an eighth-grade reading level. Each sheet in-
cluded a description of the disease for which screening could
beundertaken (includingdisease incidenceandmortality rates
asderived frompopulationestimates19,20), adescriptionof the
screening test and its benefits (primarily disease-specificmor-
tality reduction), and harms (including physical and psycho-
logical harms across the screening cascade),14 and encourage-
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ment to make a decision. We represented overdiagnosis only
indirectly by showing that incident disease rates exceed clini-
cally important outcomes (see eTable 1 in Supplement 2) and,
for prostate cancer only, overtreatment as a physical harm in
which participants received unnecessary treatment for harm-
lessdisease.Decisionsupport sheetswithineachscreeningser-
vicewere identical, except thatweprovided informationonthe
benefits and harms of screening in 1 of the 4 alternate presen-
tations: words, numbers, numbers plus narrative (narratives),
or numbers plus a framedpresentation (framed) (see eFigures
1-16 inSupplement2).Wechose these formats to representpre-
sentations of information that might affect intentions for ac-
cepting screening based on behavioral, communication, and
economic theory21-23 and other literature.10,11
Thewords presentation format used ordered descriptions
for probabilities (eg, “many,” “few,” or “very few” people af-
fected). The numbers format presented probabilities in a fre-
quency format with a common denominator (x/1000) in text
andaseparate“factsbox.”Benefitswerepresentedamongthose
screened, and harms were presented among those treated,
which may have presented a slightly more negative view of
screening than if harms had been presented among those
screened.Thenarrativeformatbuiltonanapproachthatwepre-
viouslyused24andwasdesignedtoengagereaders, informthem
about the screening decision, and model the process of
decision-making.13Narratives included (1)photographsof4 ra-
cially diverse patients in the screening age group, and (2) text
that showed individuals investigating the facts.The framedfor-
mat was designed to dissuade screening. It used a gain frame
to promote risk aversion anddiscourage screening instead of a
loss frame to promote risk-seeking in the face of the risky op-
tion of screening to detect disease. The format presented the
benefits of not screening (ie, harms avoided by not screening)
rather than theharmsof screening,whichwaspresented in the
other study arms.We tested the quantitative vignette during a
linked qualitative study, revising it based on participant feed-
back.Wethencreatedtheother interventionformatsandtested
them among administrative staff.
Measures
Study outcomes were intention to accept screening (primary
outcome) and multiple decision-making and behavioral
theory–related outcomes (secondary outcomes).
Primary Outcome
Intention isameasurableantecedent tobehavior25andexplains
asmuchas30%ofvarianceinhealthbehavior.26Thesurveymea-
sured intention toaccept screeningbyassessingpatients’plans
to be screened for the service forwhich theywere eligible dur-
ingtheusually recommendedscreening interval (1year forpros-
tatecancer screening,5years forosteoporosis screening,and10
years for colon cancer screening). The 5-point response scale
ranged fromstronglydisagree (codedas 1) to stronglyagree (5).
Secondary Outcomes
General Screening Knowledge
The survey assessed knowledge of key screening concepts
using 8 items created by the study team that addressed: the
definition of screening, false-positive results, false-negative
results, overdiagnosis (3 questions regarding harmless dis-
ease and theneed to live longenoughandhaveeffective treat-
ments in order to benefit fromscreening), overtreatment, and
thepotential for harm.Responseoptionswere true, false, and
don’t know,with scoring based on total number of correct re-
sponses, from 0 to 8.
Disease-Specific Knowledge About Overdiagnosis and Harms
The survey assessed disease-specific knowledge using 2 items
for each service thatwe adapted frompriorwork27,28 or, in the
case of osteoporosis screening, we developed. For prostate
screening, itemswere (1) “Somemencan live long,normal lives
withuntreatedprostatecancer”; and (2) “Problemswithsexual
functionandurinationarecommonsideeffectsofprostatecan-
cer treatments.” For colorectal cancer screening, items were
(1) “Most polyps in the bowel never become cancer”; and
(2) “Bleedingandtears in thebowelarecomplicationsofacolo-
noscopy.”Forosteoporosisscreening, itemswere(1)“Brokenhip
bones are uncommon before the age of 65”; and (2) “Treat-
ments forosteoporosis can sometimes result inbonedamage.”
Response options were true, false, and don’t know, with scor-
ing based on total number of correct responses, from 0 to 2.
Perceived Risk of Disease
The survey assessed patients’ perceived risk of diseasewith a
single question: “How likely is it that youwill get disease x in
thenext 10years?”The4-point response scale ranged fromnot
at all likely (coded as 1) to very likely (coded as 4).
Perceived Disease Severity
Thesurveyassessedperceivedseverityof thediseaseusing the
Lay Perceptions of Serious Illnesses Scale that had 4 items as-
sessingperceptions that the “disease is very serious,” “has se-
rious financial consequences,”“affects theway thepersonsees
himself as a person,” and “causes difficulties for those close
to thepatient” (α .66).29The5-point responsescale rangedfrom
stronglydisagree (codedas 1) to strongly agree (5). For this and
the remaining multi-item measures, we averaged items to
create a scale except as noted.
Positive Disease-Specific Screening Attitudes
Thesurveymeasureddisease-specific screeningattitudesusing
6 items developed by investigators that assessed agreement
that screening is a good idea in a healthy person of the pa-
tient’s age, not a special responsibility (reverse coded), asso-
ciatedwith little harm, owed toone’s family or physician, and
would be regretted if not done. The 5-point response scale
ranged fromstronglydisagree (codedas 1) to stronglyagree (5).
Perceived Net Benefit of Screening
We assessed perceived net benefit using a single question on
decisional balanceadapted fromourpreviouswork.27Respon-
dents were instructed to think about how they felt at that
moment about the decision to accept the screening in ques-
tion.The5-point response scale ranged fromtheharmsgreatly
outweigh the benefits (coded as 1) to the benefits greatly
outweigh the harms (5).
Presenting Benefits and Harms Information for 3 Low-Value Preventive Services Original Investigation Research
jamainternalmedicine.com (Reprinted) JAMA Internal Medicine January 2016 Volume 176, Number 1 33
Downloaded From: https://jamanetwork.com/ by a University Of North Carolina - Chapel Hill User  on 08/14/2019
Copyright 2015 American Medical Association. All rights reserved.
Values Clarity
Weassessed values clarity using the Values Clarity Subscale of
the Decisional Conflict Scale that had 3 items that assessed
whether patients agreed that they are clear about which ben-
efits andharmsmattermost andwhetherbenefits orharmsare
most important (α>.78).The5-point responsescale rangedfrom
strongly agree (coded as 0) to strongly disagree (100), so that
lower scores indicated greater clarity about personal values.
Self-efficacy for Screening
We measured self-efficacy for screening using a single item,
for each type of screening that read “How confident are you
that you could get screened for disease x if you wanted to?”
The 5-point response scale ranged from not at all confident
(coded as 1) to very confident (5).
Potential Moderators of Intervention Impact
To support exploratory analysis of moderators of the inter-
vention’s effect, we measured variables related to the ability
and motivation to process information. These included edu-
cation; numeracy (3 items, reported in aggregate as percent-
age correct, “Imagine thatwe flip a fair coin 1000 times.What
is your best guess abouthowmany times the coinwould come
up heads in 1000 flips?”; “In the lottery, the chance of win-
ning the prize is 1%. If 1000 people each buy a single ticket to
the lottery,howmanypeoplewouldwin theprize?”; “Inapub-
lisher’s sweepstakes, the chance of winning a car is 1 in 1000.
Whatpercentof tickets in this sweepstakeswinacar?”)30;need
for cognition (3 itemswith the highest item-total correlations
froman18-itemscale: “thinking isnotmyideaof fun”;“Iwould
rather do something that requires little thought than some-
thing that is sure tochallengemythinkingabilities”; and“I find
satisfaction indeliberatinghard and for longhours”)31; antici-
patedregretofnot screening (1 item, reportedona5-point scale
from strongly disagree [1] to strongly agree [5], “I would re-
gret opting not to get screened if I later tested positive for
disease.”)32; worry (3 items from the Illness Attitudes Scale,
with responses on a 5-point scale from “no” [0] to “most of
the time” [4] and summed from0 to 12: “Do youworry about
your health?”; “Are you worried you might get a serious ill-
ness in the future?”; “Does the thought of serious illness scare
you?”)33; prior screening noted onmedical chart review; and
prior information (5 investigator-developed itemswith a com-
mon stem reported on 5-point scales from “never” [1] to “al-
ways” [5] and summed for a rangeof 1-25; itemsaddressed ex-
posure to screening information through newspapers,
magazines, the Internet, television, or friends and family).We
also assessed demographics.
Potential Harm of the Intervention
Wemonitored potential harms of our intervention by assess-
ing increases in illness-related worry between preinterven-
tion and postintervention.33
Other Preintervention-OnlyMeasures
As important characteristics of the sample,we alsomeasured
general screening attitudes using 11 items, in 2 subscales, de-
veloped and validated as part of this study rather than used
as an outcome as originally planned (Jessica DeFrank, PhD,
email communication, May 5, 2015). These items were about
theperceivedbenefits of screening (α .82) and feelings of duty
or obligation to screen (α .84) andwere correlatedwith inten-
tion for screening (r = 0.25 and r = 0.35, respectively).
Sample Size and Power
We calculated our sample sizes to be able detect a mean dif-
ference in pre-post changes in intention to accept screening
of at least 0.5 points across intervention groups overall and
within specific screening services. Based on prior work, we
considered this 0.5 point difference the minimally clinically
important difference in intention to accept screening ser-
vices; this difference corresponds to a 21% reduction in
screening intention.34 Assuming 2-sided t tests with
α = .001 and a standard deviation of change of 1,35 we calcu-
lated that we would need 184 participants in each of the 4
intervention arms to give 95% power to detect this differ-
ence. This sample size provided about 80% power to detect
a 0.5-point mean change in intention in subgroup analyses
of the 3 screening services.
Statistical Analysis
We summarized sample characteristics using descriptive sta-
tistics. Per a priori plans, we tested the effectiveness of inter-
vention formats on change in intention-to-accept screening in
our overall sample, and subsequently in subgroups of screen-
ing services. We conducted analysis of covariance that in-
cluded format as the key variable of interest, baseline intent
for screening, and other covariates that differed among inter-
vention arms.We compared several approaches for assessing
change and found that all produced similar effects.36,37 Simi-
lar analyses were conducted for secondary outcomes (using
logistic regressions forbinaryoutcomes). Per apriori plans,we
first tested thedifferencebetweenall studyarmsusinganom-
nibus F test. If this test result was negative after accounting
formultiple comparisons (inwhichweconsideredP<.001 sig-
nificant), we did not pursue additional statistical testing be-
tween intervention arms. Toexaminepotentialmoderators of
the impact of the interventions on our primary outcome, we
visually depictedmoderation and added interaction terms to
themodels. To examine pre-post changes in primary and sec-
ondary outcomes, we used paired t tests for continuous out-
comes and McNemar χ2 tests for binary ones. Within sub-
groups of screening services, we repeated similar analyses
(findingsimilareffects, therebysupportingourdecisiontocom-
bine analyses).
Results
Patient Characteristics
We enrolled and randomized 775 patients to the 4 interven-
tion arms: words (n = 195), numbers (n = 192), narrative
(n = 196), or framed (n = 192) formats (Figure 1). Within each
intervention arm, patientswere distributed evenly across the
3screeningservices.Baselinecharacteristicsweremostlywell-
balanced, although those in the framed format arm were
Research Original Investigation Presenting Benefits and Harms Information for 3 Low-Value Preventive Services
34 JAMA Internal Medicine January 2016 Volume 176, Number 1 (Reprinted) jamainternalmedicine.com
Downloaded From: https://jamanetwork.com/ by a University Of North Carolina - Chapel Hill User  on 08/14/2019
Copyright 2015 American Medical Association. All rights reserved.
slightly more educated (Table 1). Baseline characteristics
were less well balanced in subgroups (eTables 2-4 in the
Supplement).
Intervention Effects
Primary Outcome: Change in Intention-to-Accept Screening
The intervention arms had high intention-to-accept screen-
ing at baseline (words, 3.56; numbers, 3.71; narrative, 3.66;
framed, 3.53out of 5.00;Table 2). The4 interventionarmsdid
not differ in change in screening intentions (adjustedP = .57).
In analyses within each arm, the narrative format had lower
intention-to-accept screening at postintervention compared
with preintervention (−0.12; 95% CI, −0.22 to −0.02 on a
5-point scale), but other interventions arms had no changes
frombaseline. In separate subgroup analyses for the 3 screen-
ing services, we observed a similar pattern of findings (see
Table 2 and eTables 5-7 in Supplement 2).
Secondary Outcomes
Overall and subgroup analyses found no statistically signifi-
cantdifferences in change in intention for screening across in-
tervention arms for any of the secondary study outcomes af-
ter accounting for multiple comparisons. However, within
intervention arms, some secondary outcomes improved from
baseline (eg, screening knowledge, screening attitudes, and
perceivednet benefit of screening; seeTable 2 andeTables 5-7
in Supplement 2).
Moderators
In theoverall sample, change in intention for screeningdidnot
differ across study arms for subgroups of patients defined by
ability, motivation, or demographics (Figure 2).
Potential Harm of the Intervention
We observed no evidence of increase in postintervention
illness-related worry.
Discussion
In a randomized clinical trial of 4 formats for presenting ben-
efits and harms of 3 screening services with low-value or po-
tentially low-value, we found no differences in change in in-
tention for screening across intervention arms. Furthermore,
while secondaryoutcomes showed small improvements from
baseline, none of these changes were sufficient to change in-
tentions to accept screening. There were no clinically impor-
tantdifferences insubgroupsofpatientsdefinedbyability,mo-
tivation, or demographics and no evidence of harm from the
interventions.
Our findings are consistent with those of systematic
reviews38 showing that patient decision aids produce in-
creases in screening knowledge and improve other decision-
makingoutcomes;however, theyalsosuggest that single,brief,
writtendecisionsupport sheets, suchas thoseused in this trial,
are unlikely to be sufficient to change intention for screening
of low-value or potentially low-value screening services, re-
gardless of their format. Decisions about screening are driven
by a complex interplay of attitudes, social norms, and self-
efficacy, many of which often strongly favor screening. Fur-
thermore, many decision-makers rely on emotions and heu-
ristic decision-making, rather than the rational processes
involved inweighing harms and benefits, and are subject to a
host of cognitive biases that make foregoing health care ser-
vices difficult.14,39,40 This suggests that either more inten-
Figure 1. CONSORTDiagram of Participant Flow
3190 Patient eligible for ≥1
exemplar service
2415 Excluded
1136 Declined participation 
58 Missed study visit
14 Excluded for other reasons 
711 Could not be contacted  
496 Ineligible after telephone
screening or service already filled 
775 Randomized
192 Randomized to receive framed
intervention
192 Received intervention
as randomized
64 PSA subgroup 
64 Osteo subgroup 
64 CRC subgroup
196 Randomized to receive
narrative intervention 
196 Received intervention
as randomized
66 PSA subgroup 
65 Osteo subgroup 
65 CRC subgroup
192 Randomized to receive
quantitative (numbers) 
intervention 
192 Received intervention
as randomized
63 PSA subgroup 
63 Osteo subgroup 
66 CRC subgroup
195 Randomized to receive
qualitative (words) intervention 
195 Received intervention
as randomized
65 PSA subgroup 
66 Osteo subgroup 
64 CRC subgroup
192 Analyzed196 Analyzed192 Analyzed195 Analyzed
8406 Patient medical charts reviewed
CRC indicates colorectal cancer; osteo, osteoporosis; PSA, prostate-specific antigen.
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sive interventionsornewapproacheswill beneeded.More in-
tensive decision support interventions for prostate cancer
screeninghavebeenshownto reduce screening intentionsand
behavior (one by 22% at 9 months),24,41 likely through their
inclusion of more detailed information and additional com-
ponents such as modeling self-discovery about harms. Such
interventionsmayhave an important role in reducing screen-
ing intentions for low-value services. However, even more
intensive interventions may not be enough.
Rather than simply intensifying current clinical interven-
tions,effectiveapproachestoreducingoveruseof low-valueser-
vices may need to take a comprehensive approach. The most
successful campaignshave targetedmultiple levels of thepub-
lic health pyramid.6 It may be that prevention and deimple-
mentationof low-valuecarewill require combinationsof inter-
ventions such as (1) patient and clinician engagement through
campaigns, like Choosing Wisely; (2) aligned recommenda-
tions and incentives42,43; (3) committed leaders and champi-
ons; (4) the time and space for change; (5) system-level
supports42,44-47; and(6)more intensiveclinicianandpatientde-
cision support than the 1-pagewritten decision support sheets
provided in this study.24,48 Possible adjunctive decision-
making interventions includehighlighting the financial andop-
portunity costs of screening, emphasizing the potential harms
of overdiagnosis and overtreatment,49 increasing the salience
of harms through video or othermedia, and testing appeals to
Table 1. Participant Characteristics at Baseline
Characteristic
No. (%)
All
Participants
(n = 775)
Intervention Arm
Words
(n = 195)
Numbers
(n = 192)
Narrative
(n = 196)
Framed
(n = 192)
Mean age, y 65 65 65 66 66
Female sex 53 54 54 53 53
Race
White 535 (69) 133 (68) 135 (70) 136 (69) 131 (69)
Black 202 (26) 52 (27) 47 (25) 52 (27) 51 (27)
Asian 15 (2) 9 (<1) 4 (2) 6 (3) 4 (2)
More than one race 20 (3) 8 (4) 6 (3) 2 (1) 4 (2)
Unknown 2 (<1) 1 (<1) 0 0 1 (<1)
Hispanic 14 (2) 3 (2) 8 (4) 1 (<1) 2 (1)
Education
<High school 17 (2) 5 (3) 3 (2) 8 (4) 1 (<1)
High school graduate 57 (7) 14 (7) 16 (8) 20 (10) 7 (4)
Some college 121 (16) 30 (15) 38 (20) 28 (14) 25 (13)
2-y degree 71 (9) 26 (13) 15 (8) 12 (6) 18 (9)
4-y degree 209 (27) 47 (24) 51 (27) 57 (29) 54 (28)
Graduate school 299 (39) 73 (37) 69 (36) 71 (36) 86 (45)
Insurance coverage 764 (99) 190 (98) 192 (100) 193 (99) 189 (98)
Type of Insurance
Medicaid 37 (5) 14 (7) 5 (3) 9 (5) 9 (5)
Medicare 327 (42) 80 (41) 76 (40) 89 (45) 82 (43)
Health maintenance organization 107 (14) 25 (13) 23 (12) 31 (16) 28 (15)
Traditional insurance 552 (71) 142 (73) 143 (74) 133 (68) 134 (70)
Other, eg, Veterans Administration 38 (5) 9 (5) 12 (6) 6 (3) 11 (6)
Excellent/very good/good health 682 (88) 168 (86) 174 (91) 168 (86) 172 (90)
Previously screened 602 (78) 151 (77) 151 (79) 150 (77) 150 (78)
Prior screeninga
Osteoporosis 146 (57) 38 (58) 36 (57) 36 (55) 36 (56)
Prostate 206 (80) 52 (80) 51 (81) 52 (79) 51 (80)
Colorectal cancer 250 (97) 61 (95) 64 (97) 62 (95) 63 (98)
Any prior bad screening experience 95 (12) 21 (11) 24 (13) 25 (13) 25 (13)
General screening attitudes
Benefits of screening, mean score,
95%; range 1-5b
3.7 3.8 3.7 3.7 3.8
Screening as a duty, mean score;
range 1-5b
3.5 3.5 3.5 3.5 3.6
Need for cognition, mean score;
range -6 to 6
1.8 1.7 1.9 1.6 1.9
Numeracy, mean score; range 0-3 1.6 1.5 1.5 1.6 1.6
a Participants with prior screening for
condition/total participants
allocated to receive information
about that screening.
bHigher scores indicate more
favorable attitudes for screening.
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Figure 2. Effect of Intervention on Change in Intent to Accept Screening, Stratified byModerators
–1.0 0.5 1.00
Change in Intent to Accept
Screening (95% CI)
–0.5
P
Value
Intervention Arm, No. of Patients
Words Nos. Narrative FramedSource
Race
White 133 134 135 131
195 192 196 192Overall
.49
.18
.68
Black 52 47 52 51
.28
Words
Numbers
Narrative
Framed
Words
Numbers
Narrative
Framed
Education
High school or less 19 18 28 8
Some college 56 53 40 43
Words
Numbers
Narrative
Framed
Words
Numbers
Narrative
Framed
4-y college degree 47 51 56 54
Graduate degree 73 69 71 86
Words
Numbers
Narrative
Framed
Words
Numbers
Narrative
Framed
Insurance type
Medicaid 14 5 8 9
Medicare 68 73 82 77
Words
Numbers
Narrative
Framed
Words
Numbers
Narrative
Framed
Health status
Fair/poor 27 18 28 20
Good/very good/
excellent
168 173 167 172
Words
Numbers
Narrative
Framed
Words
Numbers
Narrative
Framed
Traditional 92 96 84 83
HMO 15 12 17 19
Words
Numbers
Narrative
Framed
Words
Numbers
Narrative
Framed
Words
Numbers
Narrative
Framed
–1.0 0.5 1.00
Change in Intent to Accept
Screening (95% CI)
–0.5
P
Value
Intervention Arm, No. of Patients
Words Nos. Narrative FramedSource
Previously screened
Yes 151 150 149 150
.70
No 44 41 46 42
.61
.69
.30
.13
Words
Numbers
Narrative
Framed
Words
Numbers
Narrative
Framed
Worry about health
0-3 58 58 48 61
4-8 125 125 132 122
Words
Numbers
Narrative
Framed
Words
Numbers
Narrative
Framed
9-12 11 8 15 9
Words
Numbers
Narrative
Framed
Numeracy
0 37 35 30 25
1-2 117 115 128 133
Words
Numbers
Narrative
Framed
Words
Numbers
Narrative
Framed
Prior information 
0-10 39 36 43 26
Words
Numbers
Narrative
Framed
All 3 41 41 37 34
11-15 113 111 93 115
16-25 42 43 59 51
Words
Numbers
Narrative
Framed
Antic inaction regret
Agree/strongly
agree
161 162 172 164
Words
Numbers
Narrative
Framed
Other 34 29 23 28
Words
Numbers
Narrative
Framed
Words
Numbers
Narrative
Framed
Antic inaction regret indicates anticipated inaction regret; HMO, health maintenance organization.
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peripheral cues that are persuasive to those who do not cen-
trally process benefits and harms information.22,40,46
In interpretingourresults, readersshouldconsider the limi-
tations of our study. First, we tested decision support sheets
for only 3 screening services. Similar interventions for other
screening services could produce other results, particularly if
services have different rates of overuse or public visibility.
Second, some of our measures were single items or previ-
ously unvalidated measures adapted from other studies.
Different measures may produce different results.50 Third,
some characteristics differed across trial arms at baseline.
Analyses controlled for these potential confounders, but re-
sidual confounding remains a possibility. Fourth, the success
of our gain framed option depended on patients’ perceptions
that screening is the riskier option; however, we did notmea-
sure thisperceptionexplicitly.Fifth,wemayhaveslightlyover-
estimated the rate of osteonecrosis of the jaw in average-risk
individuals in the osteoporosis decision support sheet, how-
ever, this does not change net benefit of the service. Finally,
weconducted the study in4clinics in the southeasternUnited
States. To the extent that screening rates, clinician training,
local decision-making patterns, or patient characteristics (eg,
education, numeracy, insurance, presence of usual source of
care) are different, results could bedifferent in future studies.
Conclusions
Despite limitations, our study provides important insights
aboutwhat is required to change decision-making about low-
value screening services. A single brief decision support in-
tervention, regardless of format, is unlikely to be sufficient to
change intentions for screening. Alternate and additional in-
terventions should be explored.
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Invited Commentary
Patient Decision Aids for Discouraging Low-Value
Health Care Procedures
Null Findings and Lessons Learned
Judith J. Prochaska, PhD, MPH; Ashley Sanders-Jackson, PhD
Per-capitahealth care spending in theUnitedStates is dispro-
portionally higher than that of other industrialized nations,
while life expectancy is appreciably lower. In 2013, US health
care spending totaled $2.9
trillion.1 At $9255 per per-
son, thiswas42%higher than
the next highest per-capita
spender. Yet, the United States ranks 50th for life expectancy
among 221 nations and 27th out of the 34 industrialized
Organisation for Economic Co-operation and Development
(OECD) countries. With a focus on maximizing the return of
health care spending, of interest are best practices for reduc-
ing the use of medical procedures that offer low net benefit
or, at the population level, possible net harm.
In this issue of JAMA Internal Medicine, Sheridan and
colleagues2 conducted a randomized clinical trial comparing
alternative versions of printed patient decision support ma-
terials todiscourageacceptanceof low-valuepreventivehealth
services. The targeted health services were prostate cancer
screening with prostate-specific antigen (PSA) (for men ages
50-69 years), osteoporosis screening (for women ages 50-64
years), and colorectal cancer screening (for both sexes, ages
76-85years). The information,printedonasinglepage in4 for-
mats, varied only in howharms and benefits were presented.
The formatswere qualitative (words only), quantitative (with
numbers), quantitative with a narrative (a story of an indi-
vidual thinking about the numbers), and quantitative with
framing (to promote risk aversion and discourage screening).
Overall, the study showed no significant change in inten-
tion to screen preintervention to postintervention and no dif-
ference between the 4 formats. Addressing an important clini-
cal andpublichealth issue, the investigatorsand JAMAInternal
Medicinearecommendedforpublishing thesenull findings.We
interpret the findings hereinwith consideration of the study’s
patient sample, risk communication strategy, and evaluation
methods, and identify potential future research directions.
Described as a convenience sample, participants aver-
aged 65 years of age, were highly educated (>90% were col-
lege educated, many with advanced degrees), nearly all in-
sured, and all receiving continuity care within 4 selected
community-based, primary care practices. Despite attempts
to recruitpatientsnotscreenedpreviously,mosthad in thepast
completed the screening tests of interest (>80% for PSA and
nearly 100% for colorectal cancer screening). Just over one-
third (39%) of invited eligible patients enrolled. No financial
incentive was provided for study participation. Patient fac-
torspredictiveofstudyenrollmentwerenot reported. It is likely
that interest in screening related toparticipation.Notably, the
sample’s intention for screening at baseline was character-
ized as high. Unknown is how study findings generalize to
younger,more socioeconomically disadvantagedgroups, and
those without interest and prior screening experience.
The primary outcome was patient self-reported inten-
tion to accept future screening, not medical chart documen-
tation of actual screening behavior. The investigators2
acknowledged that intention is an incomplete measure, pre-
dicting a maximum of 30% variance in behavior. Research3,4
invariouswide-ranging fieldshas consistently found thatpast
behavior is the best predictor of future behavior. It is unsur-
prising then that in a patient group compliant in the pastwith
clinician screening recommendations, the effect of this low-
intensity patient-focused intervention would be null.
Somepoints areworthmentioningwith regard to the risk
communicationapproach.Althoughaimedat reducingaccep-
tanceof screening, the studymaterials usedgain-framedmes-
saging (eg, foregoingaPSA testwouldavoidbiopsy,worry, and
unnecessary treatments). Best practices suggest the utility of
gain-framed messages for promoting behavior and loss-
framedmessages for reducing a behavior.5 The decision aids
emphasized the problem of overdiagnosis, represented indi-
rectlywith reference tohowincidentdisease ratesexceedclini-
cally importantoutcomes, suchasmortalityor fractures.While
the quantified benefits were reported for the number of pa-
tients screened (eg, 1 fewerdeath inevery 1000menscreened),
the event rates for treatment complications applied only to
treatedpatients (eg, 300of 1000men treatedhave sexual dys-
functionandurinary tract problems),which the investigators2
acknowledged likely portrayed an overly negative view of
screening. The investigators2 pilot tested only the quantita-
tive vignette with patients; unknown is the degree to which
patients noted and appreciated the subtle differences in each
risk communication format. Finally, thematerials were static
without tailoring to patient race or ethnicity, personal or fam-
ilymedical history (eg, cancer, fractures), prior screening be-
havior, or current intention.Researchgenerallyhas found that
patients have greater recollection for and are more respon-
sive to tailoredhealthcommunications.6Processmeasures that
would have been useful to collect include the amount of time
patients spent reading thematerial andcomprehensibility and
perceived usefulness of the information.
Alsoof interest are clinician effects. The study’s focuswas
on patient acceptance of screening, which ostensibly would
be recommended by their health care clinicians. Unmen-
tionedwere efforts to attenuate clinician recommendation for
low-value screening practices. In the literature, standardized
protocols, groupeducation, alert systemswith reminders, and
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ongoing feedback have positively influenced clinician
behavior.7 The study’s analyses also did not adjust for clus-
tering by clinician or within clinic. One would expect shared
variance in use of preventive health services among patients
treated by the same clinician and within the same clinic.
While noneof themethodsdecreasedparticipants' inten-
tions toparticipate in the screeningprograms, small improve-
ments were found in general and disease-specific knowl-
edge, screening attitudes, and perceived net benefit, though
again, not differentially so by treatment arm. Most of the as-
sessments were study-created scales, many lacking informa-
tion on validity, internal consistency, and stability over time;
hence, the implicationof these small reported changes areun-
known. Needed are validated scales of patient behavior and
intentions regarding low-value medical practices.
Given the highly educated sample and small increases in
knowledge found, it seems that acceptance of screening was
largely unrelated to transferred knowledge, at least as com-
municated on a single-page information sheet varied only in
written presentation of risks and benefits. That is, the inter-
vention tested was brief, static, and subtle in the degree to
which the 4 formats differed.
Reducing the use of low-value health services is a com-
plex issue, with significant clinical and health policy implica-
tions. The study by Sheridan and colleagues2 provides a use-
ful vantage point for informing future efforts. Certainly,
hindsight is 20/20. In interpreting study findings, key consid-
erations included the representativeness of the sample, the
quality of the outcome measures, intervention characteris-
tics, and the fidelity of delivery. To inform clinical practice,
future study is needed with more diverse patient samples,
process measures of patient-clinician communications, and
tracking of outcomes to actual behavior. Furthermore, the
null findings suggest the need for novel approaches to dis-
suade low-value health services that move beyond 1-size-fits-
all patient education interventions. More personalized and
tailored approaches would include computer-assisted behav-
ior change coaching, applied virtual reality technologies, and
interactive digital games. Also important are strategies that
consider the dyadic nature of the patient-clinician relation-
ship. A leading National Institutes of Health research priority
and health movement backed by President Barack Obama,
personalized or precisionmedicine recognizes that variability
in response to medical treatment and prevention exists
because of individual differences in genes, environment, and
lifestyle.8 Personalized approaches tailored to familial and
genetic risk, environment, and lifestyle are worth testing for
coaching patient decision making around low-value medical
procedures. That most of the study sample had been
screened prior, likely within the clinical practice through
which the intervention was being tested, without ill-reported
effects and with intention to screen again, suggests the
appropriateness of a more personalized and multilevel
systems approach.
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